Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy
Moore, M., Gill, S., Asmis, T., Berry, S., Burkes, R., Zbuk, K., Alcindor, T., Jeyakumar, A., Chan, T., Rao, S., Spratlin, J., Tang, P.A., Rothenstein, J., Chan, E., Bendell, J., Kudrik, F., Kauh, J., Tang, S., Gao, L., Kambhampati, S.R.P., Nasroulah, F., Yang, L., Ramdas, N., Binder, P., Strevel, E.
Published in Annals of oncology (01.12.2016)
Published in Annals of oncology (01.12.2016)
Get full text
Journal Article
A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer
Beeram, M., Tolaney, S.M., Beck, J.T., Dickler, M.N., Conlin, A.K., Dees, C., Helsten, T.L., Conkling, P.R., Edenfield, W.J., Richards, D.A., Kambhampati, S.R.P., Costigan, T.M., Chan, E., Pant, S., Kalinsky, K., Burris, H.A., Becerra, C.H., Rexer, B.N., Puhalla, S.L., Goetz, M.P.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article